To evaluate the feasibility of tumor-infiltrating lymphocyte (TIL) therapy in canine patients with naturally occurring low tumor mutational burden (TMB) cancers, highlighting the significance of these cancers in the context of TIL therapy.
Key Findings:
Functional canine TIL products can be generated from low TMB tumors, suggesting potential for therapeutic application.
A subset of TILs showed reactivity to autologous tumor cells, indicating the possibility of effective TIL therapy.
TIL recognition is dependent on MHC class I, which is critical for understanding TIL functionality.
Interpretation:
The study establishes the feasibility of TIL therapy in dogs, providing a valuable model for understanding TIL efficacy in low-TMB malignancies and its potential implications for human cancer treatment.
Limitations:
Limited studies on TIL reactivity against autologous tumor cells in dogs, indicating a need for further research.
Potential differences in immune response between dogs and humans, which should be addressed in future studies.
Conclusion:
The findings pave the way for comparative trials to evaluate TIL efficacy and develop strategies to enhance responses in low-TMB malignancies, emphasizing the importance of this research in advancing cancer therapy.
